Legal & General Group
SYRE icon

Legal & General Group’s Spyre Therapeutics SYRE Stock Holding History

Legal & General Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Buy
49,141
+4,349
+10% +$317K ﹤0.01% 1653
2026
Q1 		$2.26M Sell
44,792
-11,656
-21% -$439K ﹤0.01% 1869
2025
Q4 		$1.85M Buy
56,448
+9,607
+21% +$251K ﹤0.01% 2004
2025
Q3 		$785K Buy
46,841
+11,872
+34% +$194K ﹤0.01% 2308
2025
Q2 		$523K Sell
34,969
-2,875
-8% -$42.5K ﹤0.01% 2431
2025
Q1 		$611K Buy
37,844
+354
+0.9% +$7.37K ﹤0.01% 2339
2024
Q4 		$873K Buy
37,490
+8,335
+29% +$244K ﹤0.01% 2287
2024
Q3 		$857K Buy
29,155
+5,892
+25% +$164K ﹤0.01% 2288
2024
Q2 		$547K Buy
23,263
+6,231
+37% +$210K ﹤0.01% 2392
2024
Q1 		$646K Buy
+17,032
New +$494K ﹤0.01% 2335
2022
Q3 		– Sell
-131
Closed -$2K – 3488
2022
Q2 		$2K Hold
131
– – ﹤0.01% 3490
2022
Q1 		$8K Hold
131
– – ﹤0.01% 3453
2021
Q4 		$16K Hold
131
– – ﹤0.01% 3350
2021
Q3 		$26K Hold
131
– – ﹤0.01% 3185
2021
Q2 		$23K Sell
131
-60
-31% -$10.9K ﹤0.01% 3249
2021
Q1 		$38K Sell
191
-4
-2% -$767 ﹤0.01% 2913
2020
Q4 		$38K Hold
195
– – ﹤0.01% 2878
2020
Q3 		$35K Sell
195
-72
-27% -$13.3K ﹤0.01% 2801
2020
Q2 		$62K Buy
267
+124
+87% +$23.6K ﹤0.01% 2673
2020
Q1 		$17K Sell
143
-49
-26% -$8.33K ﹤0.01% 2972
2019
Q4 		$37K Buy
192
+6
+3% +$1.18K ﹤0.01% 2945
2019
Q3 		$36K Hold
186
– – ﹤0.01% 2883
2019
Q2 		$30K Buy
186
+50
+37% +$8.64K ﹤0.01% 3021
2019
Q1 		$27K Buy
136
+39
+40% +$8.13K ﹤0.01% 2981
2018
Q4 		$18K Hold
97
– – ﹤0.01% 3120
2018
Q3 		$23K Hold
97
– – ﹤0.01% 3152
2018
Q2 		$26K Buy
+97
New +$23.9K ﹤0.01% 3084

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Legal & General Group's SYRE Position: Q2 2026 in Review

Legal & General Group increased its Spyre Therapeutics (SYRE) stake by 9.7% in Q2 2026, buying an estimated $317K and bringing the position to 49,141 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Legal & General Group first reported a position in SYRE in Q2 2018 and has held it in 27 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Legal & General Group held 49,141 shares of Spyre Therapeutics worth $4.36M as of Q2 2026.
  • Legal & General Group bought 4,349 Spyre Therapeutics shares in Q2 2026, an estimated $317K.
  • Spyre Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1653 holding.
  • Legal & General Group first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 27 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.